The Association Between Dextromethorphan Use and the Risk of Dementia.

IF 2.7 4区医学 Q2 CLINICAL NEUROLOGY

American Journal of Alzheimers Disease and Other Dementias Pub Date : 2022-01-01 DOI:10.1177/15333175221124952

Chia-Yuan Chen, Chi-Hsiang Chung, Wu-Chien Chien, Hsin-Chien Chen

{"title":"The Association Between Dextromethorphan Use and the Risk of Dementia.","authors":"Chia-Yuan Chen, Chi-Hsiang Chung, Wu-Chien Chien, Hsin-Chien Chen","doi":"10.1177/15333175221124952","DOIUrl":null,"url":null,"abstract":"Dementia is one of neurodegenerative disease without preventive medicine currently. Dextromethorphan (DXM) has been reported to reduce neuronal damage and neurodegeneration in animal and human models. The effect of DXM on the dementia has not been fully examined. We examined the medical records over 40 years old in Taiwan's National Health Insurance Research Database between 2000 and 2015 to establish matched cohorts. We used a Cox regression hazard model to identify risk factors of dementia during 16 years of follow-up, and the results indicate that a significantly lower percentage of subjects with DXM use (P < .001) developed dementia compared with those without DXM use (11.38%, 4541/39 895 vs 18.66%, 29 785/159 580). After adjustment for age and other variables [adjusted hazard ratio: .567 (95% confidence interval: .413-.678, P < .001)], this study also demonstrated that DXM use appeared to reduce the risk of developing dementia. DXM use may potentially provide a protective effect against dementia.","PeriodicalId":50816,"journal":{"name":"American Journal of Alzheimers Disease and Other Dementias","volume":"37 ","pages":"15333175221124952"},"PeriodicalIF":2.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581109/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Alzheimers Disease and Other Dementias","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15333175221124952","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Dementia is one of neurodegenerative disease without preventive medicine currently. Dextromethorphan (DXM) has been reported to reduce neuronal damage and neurodegeneration in animal and human models. The effect of DXM on the dementia has not been fully examined. We examined the medical records over 40 years old in Taiwan's National Health Insurance Research Database between 2000 and 2015 to establish matched cohorts. We used a Cox regression hazard model to identify risk factors of dementia during 16 years of follow-up, and the results indicate that a significantly lower percentage of subjects with DXM use (P < .001) developed dementia compared with those without DXM use (11.38%, 4541/39 895 vs 18.66%, 29 785/159 580). After adjustment for age and other variables [adjusted hazard ratio: .567 (95% confidence interval: .413-.678, P < .001)], this study also demonstrated that DXM use appeared to reduce the risk of developing dementia. DXM use may potentially provide a protective effect against dementia.

查看原文本刊更多论文

使用右美沙芬与痴呆症风险之间的关系

痴呆症是一种神经退行性疾病，目前尚无预防药物。据报道，右美沙芬（DXM）可在动物和人体模型中减少神经元损伤和神经变性。DXM 对痴呆症的影响尚未得到充分研究。我们研究了 2000 年至 2015 年期间台湾国民健康保险研究数据库中 40 岁以上的医疗记录，以建立匹配队列。结果表明，与未使用 DXM 的受试者相比，使用 DXM 的受试者患痴呆症的比例明显较低（P < .001）（11.38%，4541/39 895 vs 18.66%，29 785/159 580）。在对年龄和其他变量进行调整后[调整后危险比：.567（95% 置信区间：.413-.678，P < .001）]，该研究还表明，使用 DXM 似乎可以降低患痴呆症的风险。使用 DXM 有可能对痴呆症起到保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Alzheimers Disease and Other Dementias GERIATRICS & GERONTOLOGY-CLINICAL NEUROLOGY

CiteScore

5.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： American Journal of Alzheimer''s Disease and other Dementias® (AJADD) is for professionals on the frontlines of Alzheimer''s care, dementia, and clinical depression--especially physicians, nurses, psychiatrists, administrators, and other healthcare specialists who manage patients with dementias and their families. This journal is a member of the Committee on Publication Ethics (COPE).